195.22
price up icon3.28%   6.20
after-market After Hours: 194.90 -0.32 -0.16%
loading
Abbvie Inc stock is traded at $195.22, with a volume of 8.08M. It is up +3.28% in the last 24 hours and up +2.75% over the past month. AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
See More
Previous Close:
$189.02
Open:
$189.92
24h Volume:
8.08M
Relative Volume:
1.28
Market Cap:
$344.84B
Revenue:
$58.33B
Net Income/Loss:
$3.76B
P/E Ratio:
92.96
EPS:
2.1
Net Cash Flow:
$15.39B
1W Performance:
+2.60%
1M Performance:
+2.75%
6M Performance:
+6.16%
1Y Performance:
+2.90%
1-Day Range:
Value
$189.78
$197.06
1-Week Range:
Value
$187.62
$198.83
52-Week Range:
Value
$163.81
$218.66

Abbvie Inc Stock (ABBV) Company Profile

Name
Name
Abbvie Inc
Name
Phone
(847) 932-7900
Name
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Name
Employee
55,000
Name
Twitter
@abbvie
Name
Next Earnings Date
2025-04-25
Name
Latest SEC Filings
Name
ABBV's Discussions on Twitter

Compare ABBV with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - General icon
ABBV
Abbvie Inc
195.22 333.89B 58.33B 3.76B 15.39B 2.10
Drug Manufacturers - General icon
LLY
Lilly Eli Co
762.33 664.39B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
167.33 396.75B 90.63B 22.66B 16.40B 9.35
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
115.30 220.18B 55.19B 13.65B 16.81B 6.86
Drug Manufacturers - General icon
MRK
Merck Co Inc
79.29 196.16B 63.62B 16.41B 17.04B 6.49

Abbvie Inc Stock (ABBV) Upgrades & Downgrades

Date Action Analyst Rating Change
May-14-25 Downgrade Citigroup Buy → Neutral
Apr-22-25 Initiated Cantor Fitzgerald Overweight
Dec-10-24 Resumed BofA Securities Neutral
Dec-05-24 Downgrade Daiwa Securities Outperform → Neutral
Nov-22-24 Upgrade Leerink Partners Market Perform → Outperform
Nov-15-24 Initiated Wolfe Research Outperform
Nov-04-24 Upgrade Argus Hold → Buy
Oct-17-24 Initiated Bernstein Mkt Perform
Jun-05-24 Upgrade HSBC Securities Hold → Buy
May-17-24 Initiated Cantor Fitzgerald Overweight
Jan-29-24 Upgrade William Blair Mkt Perform → Outperform
Dec-18-23 Downgrade HSBC Securities Buy → Hold
Dec-11-23 Upgrade Goldman Neutral → Buy
Nov-09-23 Initiated Deutsche Bank Hold
Oct-30-23 Upgrade Barclays Equal Weight → Overweight
Oct-20-23 Resumed UBS Neutral
Sep-29-23 Initiated Raymond James Outperform
Jul-25-23 Initiated William Blair Mkt Perform
Jul-14-23 Initiated HSBC Securities Buy
Apr-05-23 Downgrade Argus Buy → Hold
Mar-01-23 Initiated Guggenheim Buy
Feb-22-23 Downgrade Wolfe Research Outperform → Peer Perform
Feb-10-23 Upgrade SVB Securities Underperform → Market Perform
Nov-18-22 Initiated Credit Suisse Outperform
Nov-08-22 Downgrade Societe Generale Buy → Hold
Aug-01-22 Downgrade Atlantic Equities Overweight → Neutral
May-23-22 Initiated SVB Leerink Underperform
May-06-22 Downgrade Daiwa Securities Outperform → Neutral
Apr-06-22 Resumed Morgan Stanley Overweight
Feb-28-22 Downgrade UBS Buy → Neutral
Feb-03-22 Reiterated BMO Capital Markets Outperform
Feb-03-22 Reiterated Barclays Equal Weight
Feb-03-22 Reiterated BofA Securities Neutral
Feb-03-22 Reiterated Goldman Neutral
Jan-13-22 Initiated Redburn Buy
Jan-12-22 Reiterated BMO Capital Markets Outperform
Dec-09-21 Resumed Wells Fargo Overweight
Nov-23-21 Upgrade Societe Generale Hold → Buy
Jul-27-21 Resumed Truist Buy
Apr-07-21 Resumed RBC Capital Mkts Outperform
Nov-10-20 Resumed Bernstein Outperform
Sep-29-20 Initiated Berenberg Hold
Jun-23-20 Upgrade Atlantic Equities Neutral → Overweight
Jun-09-20 Upgrade Wolfe Research Peer Perform → Outperform
Jun-02-20 Upgrade Argus Hold → Buy
May-18-20 Resumed BofA/Merrill Neutral
May-12-20 Upgrade JP Morgan Neutral → Overweight
May-11-20 Resumed Morgan Stanley Overweight
Apr-20-20 Upgrade RBC Capital Mkts Sector Perform → Outperform
Mar-23-20 Downgrade Societe Generale Buy → Hold
Feb-27-20 Initiated Barclays Equal Weight
Feb-06-20 Initiated Mizuho Buy
Jan-07-20 Initiated RBC Capital Mkts Sector Perform
Dec-26-19 Reiterated Cowen Outperform
Sep-26-19 Upgrade Citigroup Neutral → Buy
Aug-20-19 Upgrade Piper Jaffray Neutral → Overweight
Jun-27-19 Upgrade Wolfe Research Underperform → Peer Perform
Jun-26-19 Upgrade SVB Leerink Mkt Perform → Outperform
May-28-19 Initiated Goldman Neutral
Apr-29-19 Upgrade BMO Capital Markets Underperform → Market Perform
View All

Abbvie Inc Stock (ABBV) Latest News

pulisher
03:15 AM

Key deals this week: Chart Industries, Northwind Midstream, AbbVie, Palo Alto Networks and more - Seeking Alpha

03:15 AM
pulisher
12:26 PM

AbbVie Reports Strong Q2 2025 Financial Results - The Globe and Mail

12:26 PM
pulisher
Aug 01, 2025

AbbVie Shares Surge 3.28% on Strong Q2 Results and Analyst Upgrades, Trading Volume Ranks in Top 500 by Daily Trading Volume - AInvest

Aug 01, 2025
pulisher
Aug 01, 2025

AbbVie Shines in Earnings Call with Strong Growth - TipRanks

Aug 01, 2025
pulisher
Aug 01, 2025

Why AbbVie Stock Flew Higher on Friday - Nasdaq

Aug 01, 2025
pulisher
Aug 01, 2025

Major pharma company takes on Oregon 340B drug law - The Business Journals

Aug 01, 2025
pulisher
Aug 01, 2025

Why Is AbbVie Stock Gaining Friday?AbbVie (NYSE:ABBV) - Benzinga

Aug 01, 2025
pulisher
Aug 01, 2025

Deal Dispatch: MEG Bidding War Heats Up, L Catterton Takes Bite Out Of Kisshokichi, Sunnova's Still Shining - Benzinga

Aug 01, 2025
pulisher
Aug 01, 2025

Why AbbVie (ABBV) Stock Is Up Today - Yahoo Finance

Aug 01, 2025
pulisher
Aug 01, 2025

AbbVie’s New Study on CLL Treatment: A Potential Game Changer? - The Globe and Mail

Aug 01, 2025
pulisher
Aug 01, 2025

Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and AbbVie (ABBV) - The Globe and Mail

Aug 01, 2025
pulisher
Aug 01, 2025

AbbVie Inc. (NYSE:ABBV) Q2 2025 Earnings Call Transcript - MSN

Aug 01, 2025
pulisher
Aug 01, 2025

AbbVie Inc (ABBV) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance ... - Yahoo Finance

Aug 01, 2025
pulisher
Aug 01, 2025

Stock Analysis | Abbvie OutlookA Mixed Technical Picture Amid Divergent Analyst Ratings - AInvest

Aug 01, 2025
pulisher
Jul 31, 2025

AbbVie's Stock Dips 0.15% as Trading Volume Surges 108.9% to Rank 50th in Market Activity Behind Strong Q2 Earnings - AInvest

Jul 31, 2025
pulisher
Jul 31, 2025

M&A News: AbbVie Eyes $1B Acquisition of Gilgamesh Therapeutics - TipRanks

Jul 31, 2025
pulisher
Jul 31, 2025

AbbVie Stock Pops After Earnings Beat and Guidance Raised - MSN

Jul 31, 2025
pulisher
Jul 31, 2025

Why AbbVie Stock Slumped Today - Yahoo Finance

Jul 31, 2025
pulisher
Jul 31, 2025

Market Today: Meta and Microsoft Lead AI Surge, AbbVie Eyes Acquisition - GuruFocus

Jul 31, 2025
pulisher
Jul 31, 2025

AbbVie Raises Full-Year Sales Guidance On Skyrizi/Rinvoq Strength - insights.citeline.com

Jul 31, 2025
pulisher
Jul 31, 2025

In rumored AbbVie deal, Wall Street sees momentum for psychedelics M&A - BioPharma Dive

Jul 31, 2025
pulisher
Jul 31, 2025

Research Alert: CFRA Retains Buy Opinion On Shares Of Abbvie Inc. - 富途牛牛

Jul 31, 2025
pulisher
Jul 31, 2025

CoreWeave, Arm Holdings, AbbVie: Trending Tickers - Yahoo Finance

Jul 31, 2025
pulisher
Jul 31, 2025

AbbVie Earnings: Continued Impressive Demand for Skyrizi, Neuroscience Portfolio Support Growth - Morningstar

Jul 31, 2025
pulisher
Jul 31, 2025

AbbVie: Q2 Earnings Snapshot - The Washington Post

Jul 31, 2025
pulisher
Jul 31, 2025

Trump demands largest pharma companies slash US drug prices - Yahoo Finance

Jul 31, 2025
pulisher
Jul 31, 2025

AbbVie Stock Eyes Breakout as Pipeline and Profits Grow - MarketBeat

Jul 31, 2025
pulisher
Jul 31, 2025

Earnings call transcript: AbbVie Q2 2025 sees stock surge on earnings beat - Investing.com Canada

Jul 31, 2025
pulisher
Jul 31, 2025

AbbVie sees no outsized tariff exposure, boosts profit forecast - Reuters

Jul 31, 2025
pulisher
Jul 31, 2025

AbbVie Lifts Forecasts As Immunology Drugs Drive Growth - Finimize

Jul 31, 2025
pulisher
Jul 31, 2025

Psychedelic stocks up after report on AbbVie-Gilgamesh deal talks - Seeking Alpha

Jul 31, 2025
pulisher
Jul 31, 2025

Arm Holdings slips on guidance, AbbVie Q2 beat, Bristol-Myers outlook - Yahoo Finance

Jul 31, 2025
pulisher
Jul 31, 2025

AbbVie Beats on Q2 Earnings & Sales, Stock Up on Raised '25 EPS View - TradingView

Jul 31, 2025
pulisher
Jul 31, 2025

AbbVie Lifts Outlook, Eyes Parkinson's Assets As Next Growth Frontier - Yahoo Finance

Jul 31, 2025
pulisher
Jul 31, 2025

AbbVie Stock Pops After Earnings. What’s Driving Shares Higher. - Barron's

Jul 31, 2025
pulisher
Jul 31, 2025

AbbVie Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Jul 31, 2025
pulisher
Jul 31, 2025

AbbVie raises guidance as key drugs and pipeline deals boost growth - Crain's Chicago Business

Jul 31, 2025
pulisher
Jul 31, 2025

AbbVie (ABBV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance

Jul 31, 2025
pulisher
Jul 31, 2025

AbbVie 2nd-quarter beats expectations - The Pharma Letter

Jul 31, 2025
pulisher
Jul 31, 2025

AbbVie in Talks to Acquire Gilgamesh in $1 Billion Deal - Bloomberg

Jul 31, 2025
pulisher
Jul 31, 2025

AbbVie lifts profit forecast on strong demand for newer immunology drugs - Reuters

Jul 31, 2025
pulisher
Jul 31, 2025

Sales of Skyrizi, Rinvoq Help AbbVie Results Top Wall Street’s Forecasts - The Wall Street Journal

Jul 31, 2025
pulisher
Jul 31, 2025

AbbVie (ABBV) Tops Q2 Earnings and Revenue Estimates - Yahoo.co

Jul 31, 2025
pulisher
Jul 31, 2025

Is Now the Time to Buy AbbVie Ahead of a Pivotal Transition? - AInvest

Jul 31, 2025
pulisher
Jul 31, 2025

AbbVie raises full-year earnings guidance amid acquisition drive - Yahoo Finance

Jul 31, 2025
pulisher
Jul 31, 2025

AbbVie lifts guidance despite slump in Humira sales - MSN

Jul 31, 2025
pulisher
Jul 31, 2025

AbbVie in charts: Revenues from Humira -58%, Skyrizi +62%, Rinvoq +42% Y/Y - MSN

Jul 31, 2025
pulisher
Jul 31, 2025

AbbVie earnings beat by $0.01, revenue topped estimates By Investing.com - Investing.com South Africa

Jul 31, 2025
pulisher
Jul 31, 2025

AbbVie stock gains as company posts Q2 beat (ABBV:NYSE) - Seeking Alpha

Jul 31, 2025
pulisher
Jul 31, 2025

Earnings Snapshot: AbbVie surpasses Q2 estimates; raises FY25 EPS outlook - Seeking Alpha

Jul 31, 2025
pulisher
Jul 31, 2025

AbbVie in Talks to Buy Gilgamesh Pharmaceuticals for $1 Billion - Yahoo Finance

Jul 31, 2025

Abbvie Inc Stock (ABBV) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
drug_manufacturers_general JNJ
$167.33
price up icon 1.57%
drug_manufacturers_general NVS
$115.30
price up icon 1.37%
drug_manufacturers_general MRK
$79.29
price up icon 1.50%
drug_manufacturers_general NVO
$48.19
price up icon 2.38%
$296.88
price up icon 0.60%
Cap:     |  Volume (24h):